Identification of pyrvinium pamoate as an anti-tuberculosis agent in vitro and in vivo by SOSA approach amongst known drugs

References

• Daniel TM. The history of tuberculosis. Respir Med. 2006;100(11):1862–1870. doi: 10.1016/j.rmed.2006.08.006
   PubMed Web of Science ®Google Scholar
• Global tuberculosis report. Geneva: World Health Organization; 2019.
   Google Scholar
• Pezzella AT. History of pulmonary tuberculosis. Thorac Surg Clin. 2019;29(1):1–17. doi: 10.1016/j.thorsurg.2018.09.002
   PubMed Web of Science ®Google Scholar
• Sukhithasri V, Vinod V, Varma S, et al. Mycobacterium tuberculosis treatment modalities and recent insights. Curr Drug Deliv. 2014;11(6):744–752. doi: 10.2174/1567201811666140619121728
   PubMed Web of Science ®Google Scholar
• Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004;47(6):1303–1314. doi: 10.1021/jm030480f
   PubMed Web of Science ®Google Scholar
• Wermuth CG. Selective optimization of side activities: the SOSA approach. Drug Discov Today. 2006;11(3–4):160–164. doi: 10.1016/S1359-6446(05)03686-X
   PubMed Web of Science ®Google Scholar
• Gastaminza P, Whitten-Bauer C, Chisari FV. Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection. Proc Natl Acad Sci U S A. 2010;107(1):291–296. doi: 10.1073/pnas.0912966107
   PubMed Web of Science ®Google Scholar
• Imperi F, Massai F, Ramachandran Pillai C, et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob Agents Chemother. 2013;57(2):996–1005. doi: 10.1128/AAC.01952-12
   PubMed Web of Science ®Google Scholar
• Lamontagne J, Mills C, Mao R, et al. Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system. Antiviral Res. 2013;98(1):19–26. doi: 10.1016/j.antiviral.2013.02.001
   PubMed Web of Science ®Google Scholar
• van Cleef KW, Overheul GJ, Thomassen MC, et al. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res. 2013;99(2):165–171. doi: 10.1016/j.antiviral.2013.05.011
   PubMed Web of Science ®Google Scholar
• Weisman JL, Liou AP, Shelat AA, et al. Searching for new antimalarial therapeutics amongst known drugs. Chem Biol Drug Des. 2006;67(6):409–416. doi: 10.1111/j.1747-0285.2006.00391.x
   PubMed Web of Science ®Google Scholar
• Tang XL, Yuan CH, Ding Q, et al. Selection and identification of specific glycoproteins and glycan biomarkers of macrophages involved in Mycobacterium tuberculosis infection. Tuberculosis (Edinb. 2017;104:95–106. doi: 10.1016/j.tube.2017.03.010
   PubMed Web of Science ®Google Scholar
• Deng JH, Chen HY, Huang C, et al. Accumulation of EBI3 induced by virulent Mycobacterium tuberculosis inhibits apoptosis in murine macrophages. Pathog Dis. 2019;77(1):ftz007. doi: 10.1093/femspd/ftz007
   PubMed Web of Science ®Google Scholar
• An L, Liu R, Tang W, et al. Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs. Antiviral Res. 2014;109:54–63. doi: 10.1016/j.antiviral.2014.06.007
   PubMed Web of Science ®Google Scholar
• Mekonnen A, Merker M, Collins JM, et al. Molecular epidemiology and drug resistance patterns of Mycobacterium tuberculosis complex isolates from university students and the local community in Eastern Ethiopia. PLoS One. 2018;13(9):e0198054. doi: 10.1371/journal.pone.0198054
   PubMed Web of Science ®Google Scholar
• Kumar S, Mehra R, Sharma S, et al. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis. Tuberculosis (Edinb. 2018;108:56–63. doi: 10.1016/j.tube.2017.10.008
   PubMed Web of Science ®Google Scholar
• Gupta R, Wells CD, Hittel N, et al. Delamanid in the treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease. 2016;20(12):S33–S37. doi: 10.5588/ijtld.16.0125
   PubMed Web of Science ®Google Scholar
• AlMatar M, AlMandeal H, Var I, et al. New drugs for the treatment of Mycobacterium tuberculosis infection. Biomed Pharmacother. 2017;91:546–558. doi: 10.1016/j.biopha.2017.04.105
   PubMed Web of Science ®Google Scholar
• Salinger DH, Subramoney V, Everitt D, et al. Population Pharmacokinetics of the Antituberculosis agent pretomanid. Antimicrob Agents Chemother. 2019;63(10):e00907-19. doi: 10.1128/AAC.00907-19
   PubMed Web of Science ®Google Scholar
• Falzon D, Zellweger JP, Migliori GB, et al. Drug resistance and tuberculosis elimination in low-incidence countries. Eur Respir J. 2014;44(6):1408–1411. doi: 10.1183/09031936.00138014
   PubMed Web of Science ®Google Scholar
• Hsu JT, Yeh JY, Lin TJ, et al. Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus. Antimicrob Agents Chemother. 2012;56(2):647–657. doi: 10.1128/AAC.00125-11
   PubMed Web of Science ®Google Scholar
• Mao L, Wang J, DeGrado WF, et al. An assay suitable for high throughput screening of anti-influenza drugs. PLoS One. 2013;8(1):e54070. doi: 10.1371/journal.pone.0054070
   PubMed Web of Science ®Google Scholar
• Maroto M, Fernandez Y, Ortin J, et al. Development of an HTS assay for the search of anti-influenza agents targeting the interaction of viral RNA with the NS1 protein. J Biomol Screen. 2008;13(7):581–590. doi: 10.1177/1087057108318754
   PubMed Web of Science ®Google Scholar
• Altaf M, Miller CH, Bellows DS, et al. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis (Edinb. 2010;90(6):333–337. doi: 10.1016/j.tube.2010.09.002
   PubMed Web of Science ®Google Scholar
• Lougheed KE, Taylor DL, Osborne SA, et al. New anti-tuberculosis agents amongst known drugs. Tuberculosis (Edinb. 2009;89(5):364–370. doi: 10.1016/j.tube.2009.07.002
   PubMed Web of Science ®Google Scholar
• Ishii I, Harada Y, Kasahara T. Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front Oncol. 2012;2:137. doi: 10.3389/fonc.2012.00137
   PubMedGoogle Scholar
• Smith TC, Kinkel AW, Gryczko CM, et al. Absorption of pyrvinium pamoate. Clin Pharmacol Ther. 1976;19(6):802–806. doi: 10.1002/cpt1976196802
   PubMed Web of Science ®Google Scholar
• Xu W, Lacerda L, Debeb BG, et al. The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One. 2013;8(8):e71508. doi: 10.1371/journal.pone.0071508
   PubMed Web of Science ®Google Scholar
• Simm C, May RC. Zinc and Iron Homeostasis: target-Based drug screening as New Route for Antifungal drug development. Front Cell Infect Microbiol. 2019;9:181. doi:10.3389/fcimb.2019.00181.
   PubMedGoogle Scholar
• Tomitsuka E, Kita K, Esumi H. An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system–a unique mitochondrial energy metabolism in tumour microenvironments. J Biochem. 2012;152(2):171–183. doi: 10.1093/jb/mvs041
   PubMed Web of Science ®Google Scholar
• Tomitsuka E, Kita K, Esumi H. The NADH-fumarate reductase system, a novel mitochondrial energy metabolism, is a new target for anticancer therapy in tumor microenvironments. Ann N Y Acad Sci. 2010;1201:44–49. doi: 10.1111/j.1749-6632.2010.05620.x
   PubMed Web of Science ®Google Scholar
• Li T, Feng J, Xiao S, et al. Identification of FDA-approved drugs with activity against Stationary Phase Bartonella henselae. Antibiotics (Basel). 2019;8(2):50. doi: 10.3390/antibiotics8020050
   PubMed Web of Science ®Google Scholar
• Shen L, Niu J, Wang C, et al. High-Throughput screening and Identification of Potent broad-spectrum inhibitors of coronaviruses. J Virol. 2019;93(12):e00023-19. doi: 10.1128/JVI.00023-19
   Web of Science ®Google Scholar
• Wiegering A, Uthe FW, Huttenrauch M, et al. The impact of pyrvinium pamoate on colon cancer cell viability. Int J Colorectal Dis. 2014;29(10):1189–1198. doi: 10.1007/s00384-014-1975-y
   PubMed Web of Science ®Google Scholar
• Esumi H, Lu J, Kurashima Y, et al. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-qu inolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci. 2004;95(8):685–690. doi: 10.1111/j.1349-7006.2004.tb03330.x
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang L, Hu C, et al. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int J Oncol. 2016;48(3):1175–1186. doi: 10.3892/ijo.2016.3337
   PubMed Web of Science ®Google Scholar
• Thorne CA, Hanson AJ, Schneider J, et al. Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol. 2010;6(11):829–836. doi: 10.1038/nchembio.453
   PubMed Web of Science ®Google Scholar
• Lei B, Wei CJ, Tu SC. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J Biol Chem. 2000;275(4):2520–2526. doi: 10.1074/jbc.275.4.2520
   PubMed Web of Science ®Google Scholar
• Xu M, Zhou YN, Goldstein BP, et al. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J Bacteriol. 2005;187(8):2783–2792. doi: 10.1128/JB.187.8.2783-2792.2005
   PubMed Web of Science ®Google Scholar